Escape Bio | Developing Therapeutics for Neurodegenerative Disease_Business

COMPANYOverviewExecutive ManagementBoard of DirectorsContactPIPELINEOverviewESB1609 (S1P5 Selective Agonist)LRRK2 Kinase InhibitorsAPOEPublicationsSCIENCEPATIENTSINVESTORS & MEDIAInvestorsPress ReleasesEvents & PresentationsCAREERS CONTACT US 650.431.0100 [email protected] share precision neurologyA clinical-stage company developing novel, precisely targeted therapies for genetic neurodegenerative diseasesAt ESCAPE, we’re passionate about helping people suffering from inherited forms of neurodegeneration. Our pipeline includes candidates targeting known genetic drivers of multiple diseases. Our goal is to improve the lives of patients suffering from Alzheimer's disease, Parkinson's disease, and CNS lysosomal storage disorders.Diversified pipeline with 3 small moleculesMORE ESB1609 (AN S1P5 SELECTIVE AGONIST) HAS COMPLETED A PHASE I MULTIPLE ASCENDING DOSESTUDY MORE LRRK2 KINASE INHIBITORSMORE An approach that increases the probability of successPrecision therapies targeting specific genetic populations have already come to market for other difficult-to-treat disease areas, such as cancer.MORE Latest newsDecember 06, 2021ESCAPE Bio Appoints Mark Kaufmann as Chief Financial Officer and Chief Business OfficerMarch 31, 2021ESCAPE Bio to Present at Stifel’s 3rd Annual CNS Day [email protected] CompanySciencePipelineInvestors & MediaCareersPrivacy PolicyTerms of UsePrivacy PolicyTerms of Use Privacy PolicyTerms of Use© Escape Bio. All Rights Reserved.Julie Anne SmithPresident & Chief Executive OfficerPrior to joining E-Scape, Ms. Smith was president and chief executive officer ofNuredis, a biotechnology company focused on neurodegenerative diseases causedby long nucleotide repeats such as Huntington's disease. She previously servedas president and CEO of Raptor Pharmaceuticals, which developed andcommercialized therapies for the orphan disease nephropathic cystinosis andchronic pulmonary infections in cystic fibrosis before its acquisition by HorizonPharmaceuticals. Ms. Smith also served as chief commercial officer of EnobiaPharmaceuticals until it was acquired by Alexion in 2012.Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazymeand Bristol-Myers Squibb. Ms. Smith serves as a director on the boards of Exelixis, Inc.(EXEL) and Audentes Therapeutics (BOLD). Ms. Smith obtained her Bachelor ofScience in biology from Cornell University.